Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.

ABSTRACT:

Purpose

Persistent androgen signaling is implicated in castrate-resistant prostate cancer (CRPC) progression. This study aimed to evaluate androgen signaling in bone marrow-infiltrating cancer and testosterone in blood and bone marrow and to correlate with clinical observations.

Patients and methods

This was an open-label, observational study of 57 patients with bone-metastatic CRPC who underwent transiliac bone marrow biopsy between October 2007 and March 2010. Patients received oral abiraterone acetate (1 g) once daily and prednisone (5 mg) twice daily. Androgen receptor (AR) and CYP17 expression were assessed by immunohistochemistry, testosterone concentration by mass spectrometry, AR copy number by polymerase chain reaction, and TMPRSS2-ERG status by fluorescent in situ

SUBMITTER: Efstathiou E 

PROVIDER: S-EPMC3295561 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature